Table 2.
Summary of adverse events (AEs), as-treated population
| Patients with n (%) | AML (n = 27) | MM (n = 18) | DLBCL (n = 22) | Total (N = 67) |
|---|---|---|---|---|
| At least one AE | 26 (96.3) | 18 (100.0) | 22 (100.0) | 66 (98.5) |
| At least one treatment-related AE | 17 (63.0) | 17 (94.4) | 18 (81.8) | 52 (77.6) |
| At least one grade 3-4 AE | 23 (85.2) | 15 (83.3) | 19 (86.4) | 57 (85.1) |
| At least one grade 3-4 treatment-related AE | 13 (48.1) | 14 (77.8) | 16 (72.7) | 43 (64.2) |
| At least one serious AE | 18 (66.7) | 6 (33.3) | 10 (45.5) | 34 (50.7) |
| Treatment-related death | 1 (3.7) | 0 | 0 | 1 (1.5) |
| At least one AE leading to discontinuation | 6 (22.2) | 9 (50.0) | 8 (36.4) | 23 (34.3) |
| At least one treatment-related AE leading to discontinuation | 3 (11.1) | 7 (38.9) | 6 (27.3) | 16 (23.9) |
| At least one AE leading to dose interruption | 0 | 1 (5.6) | 0 | 1 (1.5) |
| At least one treatment-related AE leading to dose interruption | 0 | 1 (5.6) | 0 | 1 (1.5) |
| At least one AE leading to dose delay | 8 (29.6) | 8 (44.4) | 10 (45.5) | 26 (38.8) |
| At least one treatment-related AE leading to dose delay | 5 (18.5) | 8 (44.4) | 9 (40.9) | 22 (32.8) |
| At least one AE leading to dose omission | 4 (14.8) | 9 (50.0) | 10 (45.5) | 23 (34.3) |
| At least one treatment-related AE leading to dose omission | 3 (11.1) | 9 (50.0) | 10 (45.5) | 22 (32.8) |
AML acute myeloid leukemia, DLBCL diffuse large B-cell lymphoma, MM multiple myeloma